HC Wainwright & Co. maintained its ESSA Pharma [EPIX] rating to the equivalent of Buy but changed the price target to $17.0 from $10, in a research note dated 2021-01-11. That figure represents around a 41.43% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with Oppenheimer’s analysts assigning the shares to “an Outperform” rating in a research note to investors issued in late October.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Is ESSA Pharma Inc. [NASDAQ:EPIX] a Good Buy Right Now?
It should be noted that EPIX technical indicators for short, intermediate as well as long term progress have placed an overall average of 100% as Buy. The average signal changed from 100% Buy in the last week and compares with 72% Buy in the past month. Data from ESSA Pharma Inc.’s Trend Spotter indicated that the signals were Weakest. The stock current average is 0.22 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 0.17 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.14 million shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EPIX Price Performance
On Wall Street, ESSA Pharma Inc. [NASDAQ:EPIX] finished Friday’s session down -6.09% at $12.02. The stock went up to $12.90 at the same session while its lowest single day price was $11.6301. In the last five days, it saw a rise of about 0.75%, ESSA Pharma Inc. shares gained by almost 0.75% since the beginning of the year. However, the share price has dropped to as low as -9.08% below its one year high. On 01/07/21, the company shares recorded $13.22, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $11.27. The company’s shares have inclined by 109.04% in the past year. The 50-day SMA achieved is $7.75 while the 200-day SMA is $6.30. Volume dropped to 0.57 million from 0.64 million in the previous session.
EPIX Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 11.47 level, and in case of violation of this particular level, it will cause more drop to 10.91 level. On the upper level, 13.45 is still the key resistance. The stock may increase to the subsequent resistance at 12.74. The Relative Strength Index (RSI) pinned on the 14-day chart is 72.88, implying a overbought technical stance while the MACD stands at 1.32, meaning price will increase in the next trading period. Percent R indicator moved to 22.26%, implying bullish price movement. Stochastic %K at 84.43% suggest selling the stock.
What is the short interest in ESSA Pharma Inc.?
Short interest in the ESSA Pharma Inc. stock has plunged, decreasing by 3630.0 shares to total 15160.0 shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 11530.0, data from Yahoo Finance shows. The increase of 23.94% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 0.06% of the overall float for the stock.
ESSA Pharma Inc.’s Biggest Shareholders: Who Owns ESSA Pharma Inc. [EPIX]?
Filings by Soleus Capital Management LP showed that the firm now holds a total of 2,844,187 shares or roughly 9.81% of the outstanding EPIX shares. This means their shares have reduced by -528,867 from the 2,844,187 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, BVF Partners LP updated stake is worth $21,039,123. The OrbiMed Advisors LLC’s holdings currently number 1,177,483 shares at $14153345.66. According to the firm’s last 13F report, Sio Capital Management LLC shares in the company at filing stood at 656,043 shares, roughly $4,592,301.
